Funding for this research was provided by:
MSD Australia (N/A)
Received: 23 January 2019
Accepted: 2 May 2019
First Online: 21 May 2019
Ethics approval and consent to participate
: Human research ethics approval was obtained for all sites, with the need for consent waived as a Low and Negligible Risk (LNR) research project, through the Western Sydney Local Health District Human Research Ethics Committee (HREC) (HREC Ref: AU RED LNR14/WMEAD/112).
: Not applicable.
: SC, MS, SVH and DM are on the Antifungal Advisory Boards of Gilead Sciences Inc., MSD Australia and Pfizer Australia. SK is on the Antifungal Advisory Board of Pfizer Australia, MSD Australia and Mayne Pharma. TS, DM, MS, SC, SVH, NB, CK and SK have received untied grants from Gilead Sciences Inc., MSD Australia and Pfizer Australia. All other authors: none to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.